A history of transurethral resection of the prostate should not be a contra-indication for low-dose-rate $^{125}$I prostate brachytherapy: results of a prospective Uro-GEC phase-II trial

Carl Salembier, MD$^1$, Ann Henry, MD$^2$, Bradley R. Pieters, MD$^3$, Peter Hoskin, PhD$^4$ for the Uro-GEC working group of ESTRO

$^1$Department of Radiotherapy, Europe Hospitals Brussels, Belgium, $^2$University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, $^3$Department of Radiation Oncology, Amsterdam University Medical Centers/University of Amsterdam, Amsterdam, The Netherlands, $^4$Mount Vernon Cancer Centre, Northwood, United Kingdom

Abstract

**Purpose:** Early reports suggested that transurethral resection (TURP) prior to permanent seed brachytherapy (BT) results in high incontinence rates. Guidelines consider prior TURP as a contra-indication to treatment, but improvements in imaging and treatment planning may reduce this risk, and are investigated in this prospective study.

**Material and methods:** 99 men with histologically proven low- to intermediate-risk, localized prostate cancer, with a history of TURP performed at least 3 months before BT procedure were enrolled. All patients received a permanent seed implant between March 2009 and June 2015. Intra-operative interactive planning was recommended to ensure optimal accuracy of seed placement during the procedure. No supplemental external beam was allowed. Target and organ at risk contouring, definition of clinical target volume (CTV), and dosimetric parameters followed the modified GEC-ESTRO guidelines for permanent seed implants, as described an earlier report of our group. Follow-up was scheduled every 3 months for the first year, and every 6 months afterwards, with minimum follow-up of 2 years.

**Study endpoints:** the primary endpoint was the incidence of post-implant urinary incontinence. Secondary endpoints were the incidence of urinary and gastro-intestinal toxicity, the eventual impact on the sexual function, and the freedom from biochemical failure.

**Results:** The median follow-up time for these 99 patients was 49 months (min. 24, max. 96). In this series, the incontinence rate was 2% after TURP + BT and 2% in case of TURP + BT + re-TURP, ending up with a total urinary incontinence rate of 4%. Acute and late urinary toxicities were extremely low. No significant late gastro-intestinal toxicity was seen, and the 5-year biochemical non-evidence of disease (bNED) was 93%.

**Conclusions:** The excellent long-term results and low morbidity presented as well as many advantages of prostate brachytherapy over other treatments demonstrates that brachytherapy is an effective treatment for patients with transurethral resection and organ-confined prostate cancer.

J Contemp Brachytherapy 2020; 12, 1: 1–5
DOI: https://doi.org/10.5114/jcb.2020.92913

**Key words:** brachytherapy, permanent seed implant, transurethral resection of prostate.

**Purpose**

Transurethral resection of the prostate (TURP) is a surgical procedure performed under general or spinal anesthesia to remove the prostate tissue proximal to the verumontanum and distal to the bladder neck as treatment for urinary obstruction. The surgeon removes as much tissue as necessary without penetrating the prostatic capsule to allow the patient to void normally [1].

Low-dose-rate (LDR) $^{125}$I seed brachytherapy is an established treatment for men with localized low- and selected intermediate-risk prostate cancer. Both the American Brachytherapy Society (ABS) recommendations on permanent seed implant [2,3] and the Groupe de Curiethérapie-European Society for Radiotherapy and Oncology (GEC-ESTRO) guidelines [4] consider prior TURP as a relative contra-indication for prostate permanent seed brachytherapy. In many experienced
brachytherapy centers, a history of endoscopic resection of the prostate remains an absolute contra-indication to prostate brachytherapy, which is reflected in small number of publications in this area [5]. However, with more extensive experience, optimization of imaging techniques, and improved loading and dosimetry techniques, the complication rate in this group of patients appears low. More recent reports [6,7,8,9] dealing with this issue suggest that brachytherapy can be safely performed in a post-TURP patients’ group assuming modern imaging and optimized dosimetry techniques used. Unfortunately, the experience remains limited; reports are restricted and deal with small groups of patients. Against this background of early reports in the literature and further personal experience, the GEC-ESTRO Uro-GEC group developed a protocol for consistent target and organ at risk contouring, definition of clinical target volume (CTV), and dosimetric parameters, based on the GEC-ESTRO guidelines for prostate seed implantation [10], but with some specific adaptation for the post-TURP situation. Pilot data from the use of this protocol in a small cohort of patients has been presented [9] as well as a larger multi-center prospective planning study [11]. Due to wide range of different implantation techniques available in this multi-center environment, the variability between institutes has also been evaluated [11]. This feasibility planning study confirmed that in a multi-center setting and experienced brachytherapy units can achieve the dose constraints defined in this modified protocol for patients undergoing prostate post-TURP brachytherapy. With this reassurance, the Uro-GEC group of GEC-ESTRO proceeded with a prospective multi-center clinical study, in which patients were treated using this protocol with close evaluation of post-implant urinary function.

Material and methods

Selection of patients

Men with histologically proven organ-confined, low-to intermediate-risk (D’Amico risk group definition) localized prostate cancer, defined as clinical stage T1c-T2b, N0, ISUP grade group 1, 2, or 3 (Gleason score 6 or 7), with prostate specific antigen (PSA) level < 20 ng/ml, and with a history of transurethral resection (TURP) performed at least 3 months before brachytherapy procedure were enrolled in this multi-center prospective clinical trial. Other inclusion criteria were a prostate volume measured on transrectal ultrasound of less than 50 ml, the presence of a rim of prostate tissue of at least 1 cm around the post-TURP urethral defect at the postero-lateral side of the prostate, the absence of significant TURP-induced urinary incontinence, and an international prostate symptom score (IPSS) less than 15. The use of neo-adjuvant anti-androgen hormonal treatment was permitted to downsize the prostate volume or to cover waiting time until the brachytherapy procedure. No adjuvant hormonal treatment was permitted. General inclusion criteria were a WHO performance status 0-1, the absence of contra-indication for anesthesia, no prior history of irradiation of the pelvis, the absence of other oncologic malignancy except adequately treated basal cell carcinoma of the skin or other malignancy, from which the patient was disease-free for at least 5 years. All patients provided informed consent to participate. The log-rank test was used to compare biochemical non-evidence of disease (bNED) between the subsets of patients analyzed.

Treatment and follow-up

All patients received transperineal ultrasound-guided LDR $^{125}$I seed brachytherapy monotherapy according to the institute’s usual practice and technique. Intra-operative interactive planning was recommended to ensure optimal accuracy of seed placement during the procedure. No supplemental external beam was allowed. Target and organ at risk contouring, definition of CTV, and dosimetric parameters had to follow the modified GEC-ESTRO guidelines for permanent seed implants as described previously [11]. Follow-up was scheduled every 3 months for the first year, then every 6 months, and included a physical examination, PSA, and prospective physician assessment of toxicity.

Study endpoints and statistical evaluation

The primary endpoint was the incidence of post-implant urinary incontinence, which was defined as the need to use at least one pad per day. Secondary endpoints were the incidence of acute and late urinary toxicity, the incidence of gastro-intestinal side effects, and the impact on sexual function, all evaluated using the common terminology criteria for adverse effects (CT-CAE) version 4.0, and the freedom from biochemical failure, defined as time from implant to date of PSA failure (Phoenix definition, nadir + 2 ng/ml). The probabilities of freedom from biochemical failure and bPFS were estimated using the Kaplan-Meier method. To account for benign PSA bounce, patients were not considered to have PSA failures in case of a rise of the PSA by < 2 ng/ml during the first 24 months, followed by a subsequent non-hormonally induced PSA decrease. Late toxicity was defined as any toxicity occurring at > 12 months after implant. The 12-month cut-off was chosen on the basis of the half-life decay of $^{125}$I, 12 months being roughly 6 half-lives.

Results

In all, 99 patients were entered in this prospective multi-center study. All patients received a permanent seed implant in one of the six participating centers between March 2009 and June 2015. The median follow-up was 49 (range, 24-96) months. Patient characteristics are presented in Table 1.

Acute and chronic urinary toxicity

Moderate increase in urinary irritation occurred in the first three months after the treatment. None of the patients developed a greater than grade 1 acute urinary toxicity. In addition, no acute urinary retention was seen.
19 out of the 99 patients (19%) developed a more than grade I late urinary toxicity during follow-up. Further evaluation of these 19 patients showed that in 2 patients, the complaints were related to a local recurrence, 2 patients presented with late onset urinary incontinence, and 15 patients had major lower urinary tract symptoms. Four out of these 15 patients were successfully treated with symptomatic medication only; however, 11 patients underwent a re-TURP leading to a definitive re-TURP rate in this population of 10% (11 out of 99 patients). In 4 patients, this re-TURP was performed at 1-year, in 2 patients at 18-months, in 3 patients at 2-year, and in 2 patients at 4-year post-BT. Two out of these 11 patients who underwent a re-TURP developed urinary incontinence, whereas 9 patients reported a clear relief of the lower urinary tract symptoms. At last follow-up, only 8 out of the 99 patients (8%) still reported greater than grade I late urinary toxicity. Two of the 99 patients (2%) developed urinary incontinence after the brachytherapy procedure, and 2 patients (2%) developed urinary incontinence after brachytherapy and re-TURP procedures. The total urinary incontinence rate at last follow-up is thus 4% (Figure 1). The percentage of re-TURP varied between different participating centers. Evaluating the 4 major contributing centers, the incidence of re-TURP in center 1 was 10% (1 out of 10 patients), in center 2 it was 3% (1 out of 29 patients), in center 3 it was 11% (3 out of 27 patients), and in center 4 it was 28% (7 out of 25 patients).

Lower gastrointestinal toxicity

The observed lower gastrointestinal toxicity was extremely low. Some patients developed temporary grade I side effects. Only 1 out of the 99 patients (1%) developed a grade I late gastrointestinal toxicity during follow-up. Additionally, no patients presenting with perineal pain were reported.

Oncological results

For the entire cohort of 99 patients, 7 patients (7%) presented a biochemical recurrence. Two of these patients presented with a local recurrence, whereas 5 patients developed distance metastases. The overall and cancer-specific survival was 100% at 5 years. The 4- and 5-year bNED were respectively 100% and 93% for the whole cohort (Figure 2).

The actuarial bNED with ISUP grade groups was 93.8% and 90.9% for patients with ISUP grade group 1 and 2 (Gleason score of 6 and 7), respectively ($p = 0.393$). Tumor stage was not significantly associated ($p = 0.974$).

### Table 1. Patient characteristics

| Characteristics                        | Number of patients (%) |
|----------------------------------------|------------------------|
| T-classification                        |                        |
| T1a-b-c                                 | 51 (52%)               |
| T2a-b                                   | 49 (48%)               |
| ISUP grade group / Gleason score        |                        |
| Grade group 1 / VI (3 + 3)              | 67 (67%)               |
| Grade group 2 / VII (3 + 4)             | 26 (26%)               |
| Grade group 3 / VII (4 + 3)             | 6 (6%)                 |
| Pretreatment PSA (ng/ml)                | Median 6.9 (min. 1.2, max. 16) |
| Risk level                             |                        |
| Low-risk                                | 54 (55%)               |
| Intermediate-risk                       | 45 (45%)               |
| Androgen deprivation therapy            | 0 (0%)                 |
| Median follow-up time                   | 49 months (min. 24, max. 96) |

### Fig. 1. Urinary incontinence flow chart

19 out of the 99 patients (19.2%) developed > grade I late urinary toxicity during follow-up

2 patients local recurrence 2 patients urinary incontinence 15 patients major LUTS

11 patients re-TURP 4 patients symptomatic therapy

2 patients urinary incontinence 9 patients G1 at the last follow-up

Urinary > grade I late toxicity (8/99) at last follow-up = 8.08%, of which urinary incontinence (4/99) = 4.04%
with biochemical control, neither was initial PSA or risk group ($p = 0.56$).

**Discussion**

The incidence of urinary incontinence in patients treated with brachytherapy following TURP is low at 4%. Overall, there was a low incidence of acute and late urinary and gastro-intestinal toxicity combined with excellent oncological results. These results are in concordance with the experience of other institutions [12,13,14,15,16,17] and results seen in a non-TURP population [18,19,20,21,22,23].

In our series, the incontinence rate was 2% after TURP + BT and 2% in case of TURP + BT + re-TURP, with a total urinary incontinence rate of 4%.

Both the ABS recommendations on permanent seed implant [2,3] and the GEC-ESTRO guidelines [4] consider prior transurethral resection of the prostate (TURP), a relative contra-indication for prostate permanent seed brachytherapy. These recommendations were principally based on an early report from the Seattle group [5], describing their initial experience, and reporting a major risk of significant toxicity and urinary incontinence in brachytherapy patients who had undergone prior TURP. This study indicated a 17% risk of urinary incontinence.

However, subsequently, Wallner et al. reported only a 6% incontinence rate at 3 years in 19 patients treated with prostate seed implant after previous TURP, and there have been a number of retrospective reports of post-TURP brachytherapy with low urinary toxicity rates [6,8,9,24,25,26]. These are shown in Table 2.

A further feature of this series is the number of patients undergoing a repeat TURP procedure after brachytherapy. The precise indications for this have not been collected. They may represent patients with urethral stricture or benign regrowth, but it is reassuring to note that the likelihood of incontinence in this group is no higher than the patients who did not need further intervention.

The strength of these results is that they are likely to reflect real world practice across different centers in different countries. The detailed dosimetric guidelines are an important component of this and should be closely followed in post-TURP patients. These patients have alternative options for treatment including prostatectomy or external beam radiotherapy; this data suggests that the risk of incontinence with LDR brachytherapy after TURP is no greater than either of these alternatives. Unfortunately, data on sexual function was incomplete and is not sufficient to provide a useful estimate. Similarly, we cannot comment on the need for ongoing medication such as alpha blocking drugs to maintain urinary function after brachytherapy.

Our study is the first multi-center prospective study evaluating the acute and late urinary and gastro-intestinal tolerance, the incontinence rate as well as the oncological outcomes in patients treated by TURP, followed by a prostate seed implant. It has been shown that brachytherapy for patients with a prior TURP is not only effective, but also with low induced toxicity with careful patient selection, at least 3 months from TURP and seed implant, using dosimetry adapted for the post-TURP anatomy.

**Conclusions**

With the present prospective data, added to the existing retrospective literature, and with more experience in the field as well as the optimization of the imaging techniques and improved loading and dosimetry techniques following the adapted guidelines concerning the specific post-TURP situation, prostate seed implants can be performed with excellent oncological results and low urinary and gastro-intestinal toxicity.

### Table 2. Literature list

| Publication                  | Number of patients | Urinary incontinence rate                  |
|------------------------------|--------------------|--------------------------------------------|
| Wallner et al. (1997) [6]    | 19                 | 6% (at 3 years)                            |
| Moran et al. (2004) [8]      | 171                | N.A.                                       |
| Claros et al. (2009) [24]    | 16                 | 0% (average follow-up 30 months)           |
| Salembier et al. (2009) [9]  | 51                 | 0% (mean follow-up 18 months)              |
| Anguelo Latorre et al. (2013) [25] | 56                 | 1% (mean follow-up 100 months)             |
| Prada et al. (2016) [26]     | 57                 | 1.7% (mean follow-up 104 months)           |
A history of transurethral resection of the prostate should not be a contra-indication for low-dose-rate $^{125}$I prostate brachytherapy: results of a prospective Uro-GEC phase-II trial

Acknowledgements

The authors are grateful to all contributing brachytherapists and physicists from the radiation oncology centers of Brussels and Kortrijk (Belgium), London and Leeds (United Kingdom), and Deventer and Amsterdam (The Netherlands).

Disclosure

AH declares institutional research funding from NIHR, MRC, and CRUK. AH declares membership of the EAU prostate cancer guidelines group.

References

1. Chambers A. Transurethral resection syndrome - it does not have to be a mystery. AORN J 2002; 75: 156-164, 166, 168-170.
2. Nag S, Beyer D, Friedland J, Grin P et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999; 44: 789-799.
3. Davis BJ, Horwitz EM, Lee WR et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound guided permanent prostate brachytherapy. Brachytherapy 2012; 11: 6-19.
4. Ash D, Flyna A, Battermann J et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000; 57: 315-321.
5. Blasko JC, Ragde H, Grimm PD. Transperineal ultrasound guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol Suppl 1991; 137: 113-118.
6. Wallner K, Lee H, Wasserman S, Dattoli M. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys 1997; 37: 565-569.
7. Stone NN, Ratnow ET, Stock RG. Prior transurethral resection does not increase morbidity following real-time ultrasound guided prostate seed implantation. Tech Urol 2000; 6: 123-127.
8. Moran JM, Stutz MA, Gurel MH. Prostate brachytherapy can be performed in selected patients after transurethral resection of the prostate. Int J Radiat Oncol Biol Phys 2004; 59: 392-396.
9. Salembier C, Martens G, De Groote P et al. Prior transurethral resection of the prostate should not be a contra-indication for prostate seed brachytherapy. European Multidisciplinary Meeting on Urological Cancers, Barcelona 2009, November 27-29. Abstract P021-60.
10. Salembier C, Lavagnini P, Nickers P et al., on behalf of the PROBATE group of GEC ESTRO. Tumour and target volumes in permanent prostate brachytherapy: A supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol 2007; 83: 3-10.
11. Salembier C, Rijnders A, Henry A et al. Prospective multi-center dosimetry study of low-dose iodine-125 prostate brachytherapy performed after transurethral resection. J Contemp Brachytherapy 2013; 5: 63-69.
12. Joseph J, Al-Qaisib B, Ash D et al. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy. BJU Int 2004; 94: 1235-1238.
13. Zalewsky MJ, Hollister T, Raben A et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000; 47: 1261-1266.
14. Stone NS, Stock RG. 10-year biochemical and local control following real-time I-125 prostate brachytherapy. J Urol 2003; 169 (Suppl.).
15. Ragde H, Elgamal AA, Snow PB et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 1998; 83: 989-1001.
16. Grado GL, Larson TR, Balch CS et al. Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and uroscopic guidance. Int J Radiat Oncol Biol Phys 1998; 42: 289-298.
17. Cesaretti JA, Stone NN, Stock MD. Does prior transurethral resection of the prostate compromise brachytherapy quality: a dosimetry analysis. Int J Radiat Oncol Biol Phys 2004; 60: 648-653.
18. Keyes M, Miller S, Moravan V et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys 2009; 73: 1023-1032.
19. Van Gellekom MP, Moerland MA, Van Vulpen M et al. Quality of life after permanent prostate brachytherapy in relation to dosimetry. Int J Radiat Oncol Biol Phys 2005; 65: 772-780.
20. Henderson A, Bott SR, Sooriakumaran P et al. Urinary morbidity after 125I brachytherapy of the prostate. BJU Int 2004; 93: 890.
21. Leapman MS, Stone NN, Mob S et al. Urinary incontinence following prostate brachytherapy. Urology 2016; 95: 151-157.
22. Kittel JA, Reddy CA, Smith KL et al. Long-term efficacy and toxicity of low-dose-rate $^{125}$I prostate brachytherapy as monotherapy in low-, intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2015; 92: 884-893.
23. Frank SJ, Pugh TJ, Blanchard P et al. Prospective phase 2 trial of permanent seed implantation prostate brachytherapy for intermediate-risk localized prostate cancer: efficacy, toxicity, and quality of life outcomes. Int J Radiat Oncol Biol Phys 2018; 100: 374-382.
24. Claros DR, Correia JA, Ferreira LR, Vaz FP. Retrospective evaluation of urinary continence in patients submitted to brachytherapy after transurethral resection of the prostate gland. Actas Urol Esp 2009; 33: 356-360.
25. Latorre JA, García Blanco A, Payá Barceló G et al. Brachytherapy implant for patients with transurethral resection in prostate cancer. Reports Pract Oncol Radiother 2013; 18: 549-554.
26. Prada P, Anchuelo J, Blanco AG et al. Low-dose-rate brachytherapy for patients with transurethral resection before implantation in prostate cancer. Long-term results. Int Braz J Urol 2016; 42: 47-52.